Clastogenic effect of the plant alkaloid ellipticine on bone marrow cells of Wistar rats and on human peripheral blood lymphocytes

Anticancer Alkaloids from Trees: Development into Drugs

Trees have made an enormous phytochemical contribution in anticancer drugs' development more than any other life form. The contributions include alkaloids that are biosynthesized in various ways and yield. Lead alkaloids isolated from the trees are taxol and camptothecins that currently have annual sales in billion dollars. Other important alkaloids isolated from these life forms include rohitukine, harringtonine, acronycine, thalicarpine, usambarensine, ellipticine, and matrines. Studies on their mechanism of action and target on the DNA and protein of cancerous cells aided the development of potent hemisynthesized congeners. The molecules and their congeners passed/are passing a long period of historical development before approved as antineoplastic drugs for cancer chemotherapy. Some of them did not find the application as anticancer drugs due to ineffectiveness in clinical trials; others are generating research interest in the antineoplastic activity at the present and have reached clinical trial stages. Potentials in antineoplastic molecules from trees are high and are hoped to be commensurate with cancer types afflicting human society in the future.

Current strategies to target p53 in cancer

Tumor suppressor p53 is a transcription factor that guards the genome stability and normal cell growth. Stresses like DNA damage, oncogenic assault will turn on p53 function which leads to cell cycle arrest for DNA repair, senescence for permanent growth arrest or apoptosis for programmed cell death. At the late stage of cancer progression, p53 is hijacked in all forms of tumors either trapped in the negative regulator such as MDM2/viral proteins or directly mutated/deleted. Re-introduction of a functional p53 alone has been proven to induce tumor regression robustly. Also, an active p53 pathway is essential for effective chemo- or radio-therapy. The emerging cyclotherapy in which p53 acts as a chemoprotectant of normal tissues further expands the utility of p53 activators. Functionally, it is unquestionable that drugging p53 will render tumor-specific intervention. One direct method is to deliver the functional wild-type (wt) p53 to tumors via gene therapy. The small molecule strategies consist of activation of p53 family member such as p73, manipulating p53 posttranslational modulators to increase wt p53 protein levels, protein-protein interaction inhibitors to free wt p53 from MDM2 or viral protein, and restoring p53 function to mutant p53 by direct modulation of its conformation. Although most of the current pre-clinical leads are in microM range and need further optimization, the success in proving that small molecules can reactivate p53 marks the beginning of the clinical development of p53-based cancer therapy.

Interaction effects of 5-azacytidine with topoisomerase II inhibitors on CHO cells, as detected by cytogenetic analysis

Different cell treatment protocols with the hypomethylating agent 5 azacytidine (5-aza C) were used in exponentially growing Chinese hamster ovary (CHO) cells in order to test its influence on the induction of chromosomal aberrations (CAs) induced by topoisomerase II inhibitors, ellipticine (EPC) and teniposide (VM-26). Cells pre-treated with 1 microg/ml 5-aza C for 1 h during the S-phase and post-treated in the last 2 h of incubation with 0.6 microg/ml EPC or 0.04 microg/ml VM-26 showed a reduction of 48% and 45%, respectively, in the frequencies of CAs as compared to the sum value of the frequencies obtained for each drug alone. 5-aza C added to the cultures for the last 2 h before cell fixation after a 30-min pulse treatment with EPC or VM-26 caused a 38% and 28% reduction, respectively. Simultaneous treatments with 5-aza C plus EPC, or 5-aza C plus VM-26 during the last 2 h of incubation (G2-phase), showed a significant effect of CA reduction (24%) only for the combination of 5-aza C + EPC. Preliminary assays with 5-aza C alone added to the cultures at different times demonstrated its effectiveness in inducing chromosome damage during the S-phase. Since S-phase-treated CHO cells showed a higher degree of reduction in the frequencies of CAs induced by EPC and VM-26, we suggest that 5-aza C incorporation into DNA may change the topo II cleavage sites, protecting the DNA from the induction of damage, or that the hypomethylation induced by incorporation of 5-aza C into DNA may change the chromatin structure facilitating the access to DNA repair enzymes. An alternative possibility is that 5-azaC can reactivate methylated genes involved in the repair of DNA double-strand breaks induced by topo II inhibitors.

DNA damage and cytotoxicity induced in mammalian cells by a tetramethylfuroquinolinone derivative

1,4,6,8-Tetramethyl-2H-furo[2,3-h]quinolin-2-one [FQ] is an angelicin isoster characterized by a strong photosensitizing activity FQ shows a significant antiproliferative activity also in the dark, i.e., without UVA activation. The cytotoxic activity of FQ in the dark was detected in HeLa cells and in normal human lymphocytes; FQ showed notable antiproliferative effects, barely lower in comparison with ellipticine, used as a reference Similar results were obtained studying the FQ's capacity for forming chromosome aberrations. For both FQ and ellipticine, the chromosomal damage correlated closely with cell killing, when compared with ellipticine at the same levels of survival, FQ appeared to be much less genotoxic. Using alkaline elution we have investigated the ability of FQ to damage DNA. The formation of equivalent amounts of single-strand breaks (SSB) and DNA-protein cross-links (DPC) was observed; in addition, these lesions appeared to be located at the same sites in DNA. Experiments carried out with neutral elution demonstrated the formation of double-strand breaks (DSB). All these data are consistent with an inhibition of topoisomerase II; this hypothesis was confirmed performing an enzymatic test in vitro using topoisomerase II from Drosophila melanogaster embryos.

Evaluation of the genotoxic potential of the alkaloid boldine in mammalian cell systems in vitro and in vivo

Boldine is an alkaloid present in Peumus boldus (popularly called "boldo-do-chile" in Brazil) which has healing properties and is used for the treatment of gastrointestinal disorders. The possible clastogenic effect of the drug was tested in vitro on human peripheral blood lymphocytes by evaluating the induction of chromosome aberrations and sister-chromatid exchanges (SCEs). Cultures from different individuals were treated with boldine at concentrations of 10, 20 and 40 micrograms/ml of culture medium. The effect of the alkaloid was also tested in an in vivo assay using BALB/c mouse bone marrow cells. Boldine was administered to the animals by gavage at the concentrations of 225, 450 and 900 mg/kg body weight. Under the conditions used, boldine did not induce a statistically significant increase in the frequency of chromosome aberrations or SCEs in either test system.

Cytogenetic effects of the antichagasic benznidazole on human cells in vitro

Benznidazole (bz) is a widely used trypanosomicidal agent in South America. Two test systems were used to evaluate its genotoxicity in human cells in vitro: (a) human blood lymphocytes from healthy volunteers for induction of sister-chromatid exchanges (SCEs) and chromosomal aberrations (CAs); (b) a human hepatoma cell line (Hep G2) for the induction of SCEs and micronuclei (MN). In spite of being non-clastogenic on human lymphocytes, there was a significant increase in the frequency of MN on hepatoma cells treated with different doses of bz. This results support previous data which indicated the necessity of nitroreduction of nitroimidazoles to observe their mutagenic effects. Interestingly, bz induced a significant increase in the frequency of SCEs in both test systems. The sensitivity of the parameters used and the role of cellular metabolic pathways are discussed.

Genotoxicity of the isoquinoline alkaloid berberine in prokaryotic and eukaryotic organisms

Berberine, a medically important isoquinoline alkaloid, was tested for the presence of genotoxic, mutagenic and recombinogenic activities in microorganisms. This alkaloid did not show genotoxic activity with or without metabolic activation in the SOS chromotest. It was also unable to induce significant cytotoxic, mutagenic or recombinogenic effects during treatments performed under nongrowth conditions. However, in dividing cells, this alkaloid induced important cytotoxic and cytostatic effects in proficient and repair-deficient Saccharomyces cerevisiae strains. Among the different repair-deficient mutants examined, a mutant blocked in the DNA strand-break repair pathway (rad52-1) was found to be the most sensitive to the cytotoxic effect of berberine. A triple mutant blocked in the excision (rad2-6), in the mutagenic (rad6-1) and in the recombinogenic (rad52-1) repair pathways demonstrated the same sensitivity as the single rad52-1 mutant. In dividing cells, the induction of frameshift and mitochondrial mutations, as well as crossing over, showed that this alkaloid is not a potent mutagenic agent. The possible implication of DNA topoisomerases in berberine toxicity mechanisms is discussed.

The effect of the pyrrolizidine alkaloid integerrimine on the chromosomes of mouse bone marrow cells

In an investigation of the action of integerrimine on chromosomes, the bone marrow was taken as target organ. Male and female mice of the C57Bl/6 strain received a single acute dose of this pyrrolizidine alkaloid, in 2 concentrations: 18.75 and 37.50 mg/kg. Bone marrow cells were collected 6, 12 and 24 h after treatment. The analysis of metaphasic chromosomes demonstrated that chromosomal damage occurs, correlated with drug concentration. The greatest frequency of chromosomal aberrations was detected 12 h after treatment.

Dose-response function for Painter's SCE-model

The replication model for sister chromatid exchange (SCE), when introduced in 1980 by Painter, was claimed to be consistent with the one hit property of SCE. However, the argument offered in favour of the one hit property was based on a defective dose-response function, as shown in this paper, since dose as the independent parameter of any dose-response function was not included in the considerations. This missing part of the model's dose-response function is added and, by using Bessel functions, a formula for the complete dose-response function is presented. A re-examination of the newly derived function shows that, in the model, linearity holds only under certain restricted circumstances.